当前位置: 首页 >> 检索结果
302. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.
作者: D E Neafsey.;M Juraska.;T Bedford.;D Benkeser.;C Valim.;A Griggs.;M Lievens.;S Abdulla.;S Adjei.;T Agbenyega.;S T Agnandji.;P Aide.;S Anderson.;D Ansong.;J J Aponte.;K P Asante.;P Bejon.;A J Birkett.;M Bruls.;K M Connolly.;U D'Alessandro.;C Dobaño.;S Gesase.;B Greenwood.;J Grimsby.;H Tinto.;M J Hamel.;I Hoffman.;P Kamthunzi.;S Kariuki.;P G Kremsner.;A Leach.;B Lell.;N J Lennon.;J Lusingu.;K Marsh.;F Martinson.;J T Molel.;E L Moss.;P Njuguna.;C F Ockenhouse.;B Ragama Ogutu.;W Otieno.;L Otieno.;K Otieno.;S Owusu-Agyei.;D J Park.;K Pellé.;D Robbins.;C Russ.;E M Ryan.;J Sacarlal.;B Sogoloff.;H Sorgho.;M Tanner.;T Theander.;I Valea.;S K Volkman.;Q Yu.;D Lapierre.;B W Birren.;P B Gilbert.;D F Wirth.
来源: N Engl J Med. 2015年373卷21期2025-2037页
The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial protective efficacy against clinical and severe malaria disease in infants and children. We investigated whether the vaccine efficacy was specific to certain parasite genotypes at the circumsporozoite protein locus.
305. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.
作者: Upendra Kaul.;Sripal Bangalore.;Ashok Seth.;Priyadarshini Arambam.;Rajpal K Abhaichand.;Tejas M Patel.;Darshan Banker.;Atul Abhyankar.;Ajit S Mullasari.;Sanjay Shah.;Rajneesh Jain.;Premchand R Kumar.;C G Bahuleyan.; .
来源: N Engl J Med. 2015年373卷18期1709-19页
The choice of drug-eluting stent in the treatment of patients with diabetes mellitus and coronary artery disease who are undergoing percutaneous coronary intervention (PCI) has been debated. Previous studies comparing paclitaxel-eluting stents with stents eluting rapamycin (now called sirolimus) or its analogues (everolimus or zotarolimus) have produced contradictory results, ranging from equivalence between stent types to superiority of everolimus-eluting stents.
306. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.
作者: Philip Urban.;Ian T Meredith.;Alexandre Abizaid.;Stuart J Pocock.;Didier Carrié.;Christoph Naber.;Janusz Lipiecki.;Gert Richardt.;Andres Iñiguez.;Philippe Brunel.;Mariano Valdes-Chavarri.;Philippe Garot.;Suneel Talwar.;Jacques Berland.;Mohamed Abdellaoui.;Franz Eberli.;Keith Oldroyd.;Robaayah Zambahari.;John Gregson.;Samantha Greene.;Hans-Peter Stoll.;Marie-Claude Morice.; .
来源: N Engl J Med. 2015年373卷21期2038-47页
Patients at high risk for bleeding who undergo percutaneous coronary intervention (PCI) often receive bare-metal stents followed by 1 month of dual antiplatelet therapy. We studied a polymer-free and carrier-free drug-coated stent that transfers umirolimus (also known as biolimus A9), a highly lipophilic sirolimus analogue, into the vessel wall over a period of 1 month.
317. Short-Course Antimicrobial Therapy for Intraabdominal Infection.
The successful treatment of intraabdominal infection requires a combination of anatomical source control and antibiotics. The appropriate duration of antimicrobial therapy remains unclear.
|